Market revenue in 2022 | USD 1,607.2 million |
Market revenue in 2030 | USD 3,214.3 million |
Growth rate | 9.1% (CAGR from 2022 to 2030) |
Largest segment | 13-24 weeks |
Fastest growing segment | 0-12 weeks |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, MedGenome, Myriad Genetics Inc, Roche Holding AG, Qiagen NV, Labcorp Holdings Inc, Quest Diagnostics Inc, Biora Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non invasive prenatal testing market will help companies and investors design strategic landscapes.
13-24 weeks was the largest segment with a revenue share of 50.84% in 2022. Horizon Databook has segmented the North America non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.
North America is one of the developed regions with high healthcare expenditure. It accounted for 43.38% share of the global market and is expected to maintain this dominant share during the forecast period. The rapid development of next-generation sequencing and reproductive genetics is a key factor driving the market growth.
Furthermore, high R&D investments, high preterm birth rate, and increasing incidence of chromosomal abnormalities in the region are anticipated to boost the region’s non-invasive prenatal testing market.
According to Trisomy 18 Foundation, Edwards syndrome affects around 1 out of every 2,500 pregnancies in the U.S. Presence of advanced healthcare facilities, well-established research framework, and development of whole genome sequencing in the region are anticipated to boost the growth of North America non-invasive prenatal testing market.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America non invasive prenatal testing market , including forecasts for subscribers. This continent databook contains high-level insights into North America non invasive prenatal testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account